Evaluating Xeomin® for improving mobility after stroke
Official title: Upper Extremity Injection of Xeomin® and Changes in Gait Related Mobility in Adults After Stroke
Run by Wake Forest University Health Sciences · NCT04908423 · Data updated 2026-11-12
This study is testing if Xeomin® injections can help improve walking and movement in adults who have weakness on one side after a stroke.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 79 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Wake Forest University Health Sciences Academic / other |
| Locations | 1 site (Charlotte, North Carolina) |
| Status | Recruiting |
| Started | October 19, 2021 |
| Main results expected | April 2028 |
| Study ends | April 2028 |
| Registry record updated | October 26, 2026 |
| Trial ID | NCT04908423 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are ambulatory adults with hemiparesis and spasticity due to stroke who can walk at least 10 meters independently.
✕Probably not a fit
Patients with significant joint restrictions, uncorrected hearing impairments, or other neurological conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study aims to assess the impact of Xeomin® injections on gait-related mobility in adult patients with hemiparesis following a stroke. Participants will undergo standardized physical function tests, including the 10-meter walk test and the timed 'up and go' test, before and 4-6 weeks after receiving the injection. The study will utilize a one-group pretest-post-test design to measure changes in mobility and will follow up with participants approximately 12 weeks post-injection to monitor any adverse events and therapeutic duration. The overall duration of the study is planned for 2 years to facilitate adequate screening, recruitment, and follow-up.
Why it matters
Potential benefit: If successful, this study could lead to improved mobility and quality of life for stroke survivors experiencing hemiparesis.
How similar studies have gone: While similar approaches have been explored, this specific application of Xeomin® for gait improvement post-stroke is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of hemiparesis and spasticity secondary to stroke with upper and lower limb spasticity and unilateral motor and/or sensory deficit * No prior surgery to the lower limb * Able to walk at least 10 meters without physical assistance from another person and without an assistive device * Toe- ground clearance during swing phase without assistive device or orthoses * No treatment with botulinum toxin within the past 4 months Exclusion Criteria: * Passive range of motion at either the ankle, knee, or elbow joint less than 30 degrees * Participants with uncorrected hearing impairment * Weight bearing restrictions due to concurrent orthopedic injuries that would make ambulating with or without an assistive device unsafe * Speech language expression deficit (e.g., aphasia) * Absence of proprioception upon neurologic examination * Presence of fixed contractures in the upper or lower extremities not correctable to neutral * Other confounding neurological diagnoses or active acute illness (cancer, Parkinson's disease, multiple sclerosis)
Where it's running
-
Carolinas Rehabilitation
Charlotte, North Carolina, United States Recruiting
Study contacts
- Principal investigator: Mark A Hirsch, PhD — Wake Forest University Health Sciences
- Study coordinator: Mark A Hirsch, PhD
- Email: Mark.Hirsch@atriumhealth.org
- Phone: 704-355-7673
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Deep phenotyping to explore recovery in young adults after stroke
This project will test whether a detailed health and sample-collection approach (deep phenotyping) is practical and acceptable for people aged 18–55 who have had a stroke.
-
Stem cell therapy for chronic stroke recovery
This study is testing whether using a patient's own stem cells can help people with long-term stroke recovery feel better and improve their daily functioning.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Web-based therapy using action observation and mirror therapy for arm weakness after stroke
This trial tests whether a mobile telerehabilitation app delivering action observation therapy (AOT) alone or combined AOT with mirror therapy (AOT-MT) can improve upper limb function in people with subacute stroke.
-
Remote Ischaemic Conditioning for Fatigue After Stroke 2
Aat least 12 weeks after stroke, adults with post-stroke fatigue will try a simple hand-arm cuff treatment at home to see if it helps reduce fatigue.
-
Dual-task balance training plus computer-based cognitive training after stroke
In adults who recently had a stroke, the study tests whether adding computerized cognitive exercises to balance training improves balance and other recovery outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.